Association Between the Composition of the Intestinal Microbiota and Tumor Response in Locally Advanced Rectal Cancer

Trial details

Who runs it

Centre Oscar Lambret

Trial code

NCT06181201

Record updated

18 March 2026

Original description

This is an observational, single-centre study (RIPH3) for patients with rectal cancer soon to be treated with chemotherapy (+/- neo-adjuvant radio-chemotherapy) looking at the relationship between the composition of the gut microbiota before treatment and the tumour response after chemotherapy +/- radio-chemotherapyRead full original descriptionShow less

Association Between the Composition of the Intestinal Microbiota Before Treatment and the Tumor Response After Induction Chemotherapy Followed or Not by Neo-adjuvant Radio-chemotherapy in Locally Advanced Rectal Cancer

This is an observational, single-centre study (RIPH3) for patients with rectal cancer soon to be treated with chemotherapy (+/- neo-adjuvant radio-chemotherapy) looking at the relationship between the composition of the gut microbiota before treatment and the tumour response after chemotherapy +/- radio-chemotherapy

Inclusion: Histologically proven stage II and III adenocarcinoma of the lower and middle rectum; Patient undergoing preoperative treatment with induction chemotherapy (Folfirinox) followed or not by radio-chemotherapy of the Cap50 type; Male or female patient aged 18 years or older; Normal weight, overweight or moderately obese (BMI between 18.5 and 34.9); Patient residing in the Lille metropolitan area; Patient affiliated to a French social protection scheme; Patient having given his non-opposition.

Exclusion: History of other concurrent cancers; Presence of an intestinal (internal or external) or external urinary diversion; Uncooperative patient for geographical, family, social or psychological reasons; Limited legal capacity or legal incapacity.

ClinicalTrials.gov NCT06181201